Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers RallyBenzinga · Sep 29, 2026
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease TranscriptSeeking Alpha · Sep 29, 2026
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye DiseaseMarketBeat · Sep 29, 2026
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye DiseaseBusiness Wire · Sep 29, 2026
Aldeyra Therapeutics to Host Regulatory Update WebcastBusiness Wire · Sep 28, 2026Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.09 | -$0.09 | Miss |
| May 7, 2026 | -$0.13 | -$0.06 | Beat |
| Feb 27, 2026 | -$0.14 | -$0.11 | Beat |
| Nov 5, 2025 | -$0.17 | -$0.13 | Beat |
| Aug 7, 2025 | -$0.21 | -$0.16 | Beat |
| May 14, 2025 | -$0.25 | -$0.17 | Beat |